| HOME >> BIOLOGY >> TECHNOLOGY |
Depreciation and amortization 4,460,069 3,919,267
Warrant expense 2,100,000 -
Stock-based compensation 1,931,439 3,404,063
Deferred rent and credit on lease
concession (75,060) (15,957)
Amortization of premium on
marketable securities (39,687) 204,525
(Gain) or loss on disposal of fixed
assets - 23,185
Advance payment for sale of Keflex - (1,000,000)
Changes in:
Accounts receivable (384,273) 574,751
Inventories 1,389,457 (1,857,939)
Prepaid expenses and other current
assets 539,780 (885,432)
Deposits other than on property
and equipment 304,151 (30,096)
Accounts payable (625,984) 599,249
Accrued expenses and advances (2,260,048) 534,236
Deferred product and contract revenue (189,000) 189,000
Net cash used in operating
activities (35,260,711) (36,331,302)
Cash flows from investing activities:
Purchase of marketable securities (5,867,519) (13,764,736)
Sale and maturities of marketable
securities 6,430,000 24,355,000
Purchases of property and equipment (1,396,954) (300,929)
Deposits on property and equipment - (250,000)
Proceeds from sale of fixed assets - 25,000
Change i
'/>"/>
| SOURCE MiddleBrook Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |